ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

Adjuvant BC Therapy Is Topic Of NIH Consensus Conference.

January 28, 2000

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

June 27, 2014

In Brief: Florida Osteopaths Join Medical Examiners, Nullify State’s Law Supporting Laetrile

January 18, 1985

Capitol Hill: Sen. Harkin Introduces NIH Funding Bill That Boosts Budget to $46.2 Billion by 2021

July 25, 2014

O’Neill Recounts Private Meeting To Increase Cancer Appropriations

May 3, 1991

GSK’s Votrient Approved For Advanced Kidney Cancer

October 30, 2009